If you have been reading about Angiotensin IV and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-02. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
An ideal beam-splitter transmits and reflects 50% of the incident radiation. However, as any material has a limited range of optical transmittance, several beam-splitters may be used interchangeably to cover a wide spectral range. In a simple Michelson interferometer, one beam passes twice through the beamsplitter but the other passes through only once. To correct for this, an additional compensator plate of equal thickness is incorporated. For the mid-IR region, the beamsplitter is usually made of KBr with a germanium-based coating that makes it semi-reflective. KBr absorbs strongly at wavelengths beyond 25 μm (400 cm−1), so CsI or KRS-5 are sometimes used to extend the range to about 50 μm (200 cm−1). ZnSe is an alternative where moisture vapour can be a problem, but is limited to about 20 μm (500 cm−1). CaF2 is the usual material for the near-IR, being both harder and less sensitive to moisture than KBr, but cannot be used beyond about 8 μm (1,200 cm−1). Far-IR beamsplitters are mostly based on polymer films, and cover a limited wavelength range.
"Half and half" or "Half-and-half" is a mixture of milk and cream, which is often used in coffee and with breakfast cereals. In the United States, half and half is a common liquid product produced by dairy companies in premixed form. It was invented by William A. Boutwell of Boutwell Dairy in Lake Worth Beach, Florida, which distributed the blend regionally between 1927 and 1956. In the United States, half-and-half must contain between 10.5 and 18 percent milkfat. It is pasteurized or ultra-pasteurized, and may be homogenized. The following optional ingredients may also be used:
=== United States === In January 2009, the Alfred P. Sloan Foundation funded the Woodrow Wilson Center, the Hastings Center, and the J. Craig Venter Institute to examine the public perception, ethics and policy implications of synthetic biology. On July 9–10, 2009, the National Academies' Committee of Science, Technology & Law convened a symposium on "Opportunities and Challenges in the Emerging Field of Synthetic Biology". After the publication of the first synthetic genome and the accompanying media coverage about "life" being created, President Barack Obama established the Presidential Commission for the Study of Bioethical Issues to study synthetic biology. The commission convened a series of meetings, and issued a report in December 2010 titled "New Directions: The Ethics of Synthetic Biology and Emerging Technologies." The commission stated that "while Venter's achievement marked a significant technical advance in demonstrating that a relatively large genome could be accurately synthesized and substituted for another, it did not amount to the "creation of life". It noted that synthetic biology is an emerging field, which creates potential risks and rewards. The commission did not recommend policy or oversight changes and called for continued funding of the research and new funding for monitoring, study of emerging ethical issues and public education. Synthetic biology, as a major tool for biological advances, results in the "potential for developing biological weapons, possible unforeseen negative impacts on human health ... and any potential environmental impact".
Sources: en.wikipedia.org
=== Recommended levels === Various government institutions have proposed different recommendations for the amount of daily intake of vitamin D. These vary according to age, pregnancy, or lactation, and the extent assumptions are made regarding skin synthesis. Older recommendations were lower. For example, the US Adequate Intake recommendations from 1997 were 200 IU/day for infants, children, adults to age 50, and women during pregnancy or lactation, 400 IU/day for ages 51–70, and 600 IU/day for 71 and older. Conversion: 1 μg (microgram) = 40 IU (international unit). For dietary recommendation and food labeling purposes government agencies consider vitamin D3 and D2 bioequivalent.
It also made US economic and military aid, including arms sales, dependent on countries aligning with US anti-drug policies. Later, the terms "major illicit drug-producing country" and "major drug-transit country" were defined in the act; as of 1986, the president has been required to annually determine which countries fit those definitions. Those not adequately cooperating with counter-drug efforts would not be eligible to receive US financial aid, although the president could and has provided waivers to individual countries. The so-called "majors list" has influenced how US assistance money is used internationally in the war on drugs, although in recent years, it has remained relatively static and lost a degree of relevancy. In September 2023, President Biden added China to the majors list, citing its production of precursor chemicals. Foreign anti-drug initiatives initially focused on Latin America, and expanded globally over time. Since the 1970s, billions of US aid dollars have been directed to anti-drug activity in Latin America. The US initially treated drug control as a law enforcement issue in foreign countries, providing assistance to police forces. In the 1980s, the US increasingly involved the military and private security firms, to provide training and support to armed forces in drug-producing and transit countries. As of 2024, the DEA has, in addition to 241 domestic offices, 93 foreign offices in 69 countries.
=== Scintigraphy/radionuclide imaging === Scintigraphy can be used to measure the extent and distribution of the amyloid throughout the body, including the liver, kidney, spleen, and heart. A radiolabelled serum amyloid P component can be administered to a patient intravenously and the P component pools to the amyloid deposit proportional to the size of the deposit. The labeling of the P component can then be pictured by a gamma camera. Technetium radionuclide scans can now reliably diagnosis cardiac amyloidosis, with certain scanning methods having greater than 99% sensitivity (but only 91% specific for amyloidosis). In this method of imaging, radiolabeled technetium is injected into the body where it binds to cardiac amyloid deposits. A subsequent scan is taken to determine where the tracer stays, therefore highlighting the amyloid deposition in the heart. This method allows for a noninvasive definitive diagnosis of cardiac amyloidosis (as in the past an endomyocardial biopsy was required)
Sources: en.wikipedia.org
== Production == The film was first announced in October 2014 as a live action adaptation of Dark Horse Comics' Polar, developed by Dark Horse Entertainment and Constantin Film. A spec script for the film by Jayson Rothwell was purchased. In October 2017, Mads Mikkelsen signed on to star in the film. In February 2018, Vanessa Hudgens, Katheryn Winnick and Matt Lucas joined the cast with Netflix onboard to distribute the film. Filming began early February 2018 in Orono, Ontario, Canada, and continued around February 23 in Toronto, Ontario, with Swedish director Jonas Åkerlund at the helm. Among various filming locations used was the residence of musician Deadmau5, for the opening scene. In September 2018, Deadmau5 announced that he was in the process of producing the film's original score. Netflix started streaming the film on January 25, 2019, with Deadmau5 releasing the soundtrack on the same day.
Perfumes contain chemicals that vaporize at different temperatures and at different rate in scent accords, known as notes. Atmospheric water vapor is found near the earth's surface, and may condense into small liquid droplets and form meteorological phenomena, such as fog, mist, and haar. Mercury-vapor lamps and sodium vapor lamps produce light from atoms in excited states. Flammable liquids do not burn when ignited. It is the vapor cloud above the liquid that will burn if the vapor's concentration is between the lower flammable limit (LFL) and upper flammable limit (UFL), of the flammable liquid. E-cigarettes produce aerosols, not vapors.
=== Valve === Faliszek's and Wolpaw's writings led to them being hired by Valve circa 2005. Along with Wolpaw and Marc Laidlaw, Faliszek helped to create the storylines for the Half-Life and Portal series, along with having personally written the story for Left 4 Dead. He was also involved with Valve's work in virtual reality (VR) through the HTC Vive. In May 2017, Faliszek announced that after twelve years with Valve, he had left the company earlier in the year to work on unannounced projects.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.